Kidney Cancer Diagnostics Market
Kidney Cancer Diagnostics Market Analysis By Indication (Renal Cell Carcinoma, Transitional Cell Carcinoma, Kidney Sarcoma, Wilms Tumor & Kidney Lymphoma Kidney Cancer), By Test, By End User and By Region Forecast - 2022 To 2032
Analysis of Kidney Cancer Diagnostics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Kidney Cancer Diagnostics Market Outlook 2022 to 2032
The global kidney cancer diagnostics market is projected to expand steadily at a CAGR 7% value, during the forecast period 2022 to 2032. In the year 2022, the market size is projected to expand and gain a global market valuation of US$ 800 Million. Considering this increasing growth and the booming demand in the global market, the kidney cancer diagnostics market is expected to reach US$ 1.4 Billion by 2032.
Cancer diagnostics is the process of identifying biomarkers, enzymes, and other signs that can be used to detect a malignant tumor. Diagnostic testing is utilized to confirm or rule out illness, follow progression of the disease, and schedule and assess treatment outcomes. Cancer diagnostic procedures include imaging, laboratory tests (including tumor marker tests), tumor biopsy, endoscopic examination, genetic testing, and surgery.
| Report Attributes | Details |
|---|---|
| Expected Market Value in 2022 | US$ 800 Million |
| Projected Market Value in 2032 | US$ 1.4 Billion |
| Global Growth Rate (2022 to 2032) | CAGR of 7% |
| Anticipated Market Share of the U.S Market (2022) | 35% |
| Expected Growth Rate of the Chinese Market (2022 to 2032) | 5.8% CAGR |
| Prominent Kidney Cancer Diagnostics Service Providers | Myriad Genetics Inc.; NeoGenomics Laboratories; NanoString Technologies Inc.; Sysmex Corporation; Rosetta Genomics; Illumina Inc.; Glenmark; Cobolong; Quest Diagnostics Incorporated; Roche Holding AG; Thermo Fisher Scientific Inc.; Abbott Laboratories |
Cancer diagnostics refers to the process of identifying many proteins, biomarkers, and symptoms that lead to the detection of the presence of a malignant tumor in a patient. The identification of certain proteins and biomarkers that are frequent in cancer disorders aids in the diagnosing procedure. The process of detecting cancer necessitates the employment of specialized technology and devices.
The market is largely driven by a rise in the frequency of kidney cancer and rising R&D spending by pharmaceutical firms. According to a research released in July 2021 by the International Kidney Cancer Coalition, over 431,000 persons worldwide are afflicted with kidney cancer each year.
Furthermore, according to the American Cancer Society 2022, around 431,328 people will be diagnosed with kidney cancer globally in 2022. As a result of the rising prevalence of kidney cancer, demand for kidney cancer therapies and diagnostics is predicted to rise throughout the forecast period.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
2017 to 2021 kidney cancer diagnostics market Demand Analysis vs. Forecast 2022 to 2032
According to market research and competitive intelligence provider Fact.MR- the market for kidney cancer diagnostics reflected a value CAGR of 5.8% during the historical period, 2017 to 2021. In recent years, the number of individuals living with kidney cancer has steadily climbed. Renal cancer has been shown to be more common in the elderly population, which is projected to fuel growth in the worldwide kidney cancer diagnostics market in the next few years and decades.
Several private organizations and government groups worldwide are attempting to increase awareness about kidney cancer. People's increased attentiveness and lifestyle changes are major factors driving market development. With the rising frequency of kidney cancer, future generations will benefit from more accessible, economical, and diagnosis-associated kidney cancer therapy. Technological advancements in equipment, increases in healthcare spending, and rising demand for blood chemistry testing for kidney cancer diagnostics are driving market expansion, which is predicted to grow at a 7% CAGR from 2022 to 2032.
Prominent Growth Drivers Influencing kidney cancer diagnostics market
Technological innovations to boost the global market demand
The medical device industry is a diversified, inventive, and fast-paced industry. From telemedicine to intelligent machines, robotic surgery, and 3D printing, technology is fast advancing and altering the healthcare business. Increased public and government expenditure in the healthcare sector, as well as rising demand for kidney cancer molecular diagnostics, are driving the market forward.
Improved versions of prominent diagnostic tools will almost definitely replace them. Governments throughout the world are taking various initiatives to boost kidney cancer detection systems, with an emphasis on R&D. Makers of kidney cancer diagnostic systems and healthcare providers have begun to provide tailored patient care for kidney cancer therapy, as well as access to entire end-to-end medical device goods and services. They are focusing on product prototype development and improvement, as well as minimizing operating expenses.
Due to developments in medical technology, the worldwide market for kidney cancer diagnostics is also projected to witness the launch of novel tests that may concurrently slow the pace of tumor formation between several stages of kidney cancer.
Novel Biomarkers for the Diagnosis of Kidney Cancer to boost Overall Productivity
Through enhanced detection technology and equipment, increasing understanding of some cancer biomarkers is generating a major business potential for treating cancer patients. Technological advances in the field of biotechnology have enabled the identification of potential cancer biomarkers, and some of these biomarkers have been commercialized. As a consequence, the development of new diagnostic biomarkers is opening up attractive potential for the growth of the cancer diagnostics market.
According to the study "The Early Diagnostic and Prognostic Value of BIRC5 in Clear-Cell Renal Cell Carcinoma Based on the Cancer Genome Atlas Data," published in the Karger Journal in April 2022, high BIRC5 expression is a key indicator of ccRCC prognosis, making BIRC5 an excellent biomarker for predicting patient prognosis in ccRCC. BIRC5 might be a good biomarker for detecting ccRCC early. As a result, the use of various techniques in the diagnosis of ccRCC cancer is likely to enhance the market, as the availability of such techniques may aid in the early detection of ccRCC cancer. Such benefits are expected to skyrocket the demand during 2022 to 2032.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Could Possibly Hinder Kidney Cancer Diagnostics market Demand?
Surge in Treatment Costs will restrict Market Growth
Numerous regulatory investigations are necessary to get permissions, and as a result, moving discoveries from the discovery stage to the market for commercial usage is exceedingly expensive.
The vast majority of kidney cancer cases are discovered at a late stage. The severity of cancer and its diagnosis influence patients' and physicians' decisions to pay the high expense of therapy, even if the prognosis is only marginally better.
Over the projection period, the global cancer diagnostics market may face headwinds due to low clinical trial success rates and high costs. Such incidences if repeated during the forecast period, can stymie the growth.
Category-wise Insights
Which Test Type is forecast to gain the Maximum Market Share?
Immunohistochemistry will continue to dominate the Global Market
The immunohistochemistry category is expected to lead the global kidney cancer diagnostics market in 2022 and is likely to retain its dominance throughout the forecast period. The segment is predicted to gain a global market share of 65% by 2022. As immunohistochemistry is extensively used to identify kidney cancer and other disorders requiring antigen-antibody interactions, the rise in cancer incidence is a key driver driving market expansion. Immunohistochemistry is a microscopy method used to detect antigens and macromolecules contained in cells, as well as enzymes, tumor suppressor genes, antigens, and tumor cell proliferation.
Immunohistochemical methods are increasingly being used in the pathophysiology of renal neoplasms. Immunohistochemistry demand is increasing as a result of increased product approvals and the advent of immunohistochemistry solutions for kidney cancer detection. Demand for immunohistochemistry is predicted to rise in the next few years as a result of increased drug research and development activities, rising chronic illness prevalence, and an increase in the number of diagnostic facilities. Such incidences will propel the demand by 2x during the forecast period.
Will Hospital Associated Labs be Primary End Users of Kidney Cancer Diagnostics Services?
In 2022, the hospital-associated labs segment is expected to hold the major portion of the kidney cancer diagnostics market by type, accounting for almost 40% of the global market share. The burden of lowering the incidence of kidney cancer is carried on to hospitals and medical research groups as they try to create novel diagnostic and treatment approaches.
In hospital-affiliated labs, urine samples are submitted to specific tests to check for minute quantities of blood and other chemicals that aren't visible to the human eye. Growing use of devices in hospital-associated labs for the identification of kidney cancer and severe infections is predicted to fuel market growth over the next ten years.
Many hospitals are growing their capacity and adopting medical tools for kidney cancer diagnostics, and they've undertaken a range of tactics to get the required equipment, assure an adequate personnel, and upgrade their facilities and hence propel the market growth.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Analysis
What is the Outlook of the U.S Kidney Cancer Diagnostics Market?
Rising Cancer Cases and increasing hospitalization rates will boost Market Demand
The U.S market will be the most lucrative market for kidney cancer diagnostics during the forecast period. As per Fact.MR, the US market is expected to gain a market share of 35% in 2022. According to GLOBOCAN 2020 figures, the expected number of kidney cancer cases in the USA was 60,347.
According to the American Cancer Society's projections for 2022, about 79,000 new cases of kidney cancer will be detected in the United States in 2022. The market in the United States is predicted to develop rapidly due to an increase in the number of patients with chronic illnesses, the frequency of kidney cancer, and the country's large number of healthcare facilities.
The availability of favorable reimbursement regulations, as well as high healthcare expenditure and recent breakthroughs in diagnostic instruments for transitional cell carcinoma renal cancer therapy, are projected to boost market growth in the United States. The market for kidney cancer diagnostics in the United States is predicted to grow 1.4x by 2032.
What can be expected from the Chinese market for kidney cancer diagnostics?
Increasing Consumer Awareness to boost Regional Demand
China has emerged as one of the most profitable markets for the marketing of kidney cancer diagnostics. Sales of kidney cancer diagnostic equipment are fast expanding in China. Growing patient awareness, decreasing medication manufacturing costs, and an increased patient base suffering from illnesses such as renal cell carcinoma are predicted to drive the Chinese market.
In China, where economic prospects are promising, companies are working on extending their product portfolios, diversifying their company operations, cutting costs, boosting customer contentment, and enhancing kidney cancer diagnostic reliability. According to Fact.MR's estimate, the Chinese kidney cancer diagnostics business is predicted to grow at a CAGR of roughly 5.8% between 2022 and 2032.
Start-up Scenario
- Klotho Therapeutics, located in the United States, creates recombinant versions of the human klotho protein to cure chronic kidney disease. In animal models, the solution was shown to greatly reduce the risk of chronic kidney disease (CKD) and acute renal failure (ARF). It also has the potential to be used to treat various conditions including cancer, sarcopenia, and aging-related illnesses.
- Kantam Bio, established in the United States, creates biomarkers to detect AKI and cancer in its early stages. KB-1801, the company's flagship medication candidate, is now in preclinical research for the prevention of acute renal damage following heart surgery. The medication prevents inflammation of the kidneys, lungs, and uterus by inhibiting the activation of the uridine diphosphate (UDP) glucose or P2Y14 receptor. In addition, the company is working on therapies and diagnostics for delayed graft function disease, cystic fibrosis, and female reproductive tract inflammatory illnesses.
Competitive Landscape
A wide number of firms are making major contributions to the growth of the renal cancer therapy industry. Manufacturers of kidney cancer diagnostic tools are collaborating with local health ministries and medical administrations to evaluate the treatment diagnosis's impact on kidney cancer patients. Medical organizations and worldwide pharmaceutical industry leaders are doubling down on the development of advanced kidney cancer diagnostics. Product innovation and continued R&D initiatives to create sophisticated technologies have assisted market expansion.
- Glenmark Pharma launched SUTIB, a generic kidney cancer medication, in India in February 2021. Sunitinib, an oral multikinase inhibitor (MKI), is beneficial in treating patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. Sunitinib is an oral MKI that operates by inhibiting multiple enzymes that stimulate cell proliferation. It is also authorized for people suffering from specific types of pancreatic neuroendocrine tumors. The medicine is priced at Rs 7000 (50 mg), Rs 3600 (25 mg), and Rs 1840 (12.5 mg) each month, which is roughly 96% less than the MRP of the originator brand. The US Food and Drug Administration has also authorized sunitinib (US FDA).
- Cabolong, a marketed generic of Cabozantinib, was launched in September 2021 from MSN Labs for the treatment of renal cell carcinoma. Cabolong is produced at MSN Labs' facility, which has been authorized by strict worldwide regulatory agencies such as the US FDA and EU GMP.
Key Segments Profiled in the Kidney Cancer Diagnostics Market Study
-
By Test:
- Immunohistochemistry
- Complete Blood Count
- Urine Test
- Blood Chemistry
-
By Indication:
- Renal Cell Carcinoma
- Transitional Cell Carcinoma
- Kidney Sarcoma
- Wilms Tumor
- Kidney Lymphoma
-
By End User:
- Hospital-associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
-
By Region:
- North America
- Latin America
- Europe
- Japan
- APEJ
- Middle East Africa
Table of Content
- 1. Global Market to Executive Summary
- 2. Global Market Overview
- 3. Global Market Analysis and Forecast By Test Type
- 3.1. Immunohistochemistry Kidney Cancer
- 3.2. Urine Analysis
- 3.3. Complete Blood Count
- 3.4. Blood Chemistry Test
- 4. Global Market Analysis and Forecast by End User
- 4.1. Hospital Associated Labs
- 4.2. Independent Diagnostic Laboratories
- 4.3. Cancer Research Institutes
- 4.4. Others
- 5. Global Market Analysis and Forecast By Indication
- 5.1. Renal Cell Carcinoma
- 5.2. Transitional Cell Carcinoma
- 5.3. Wilms Tumor
- 5.4. Kidney Lymphoma
- 5.5. Kidney Sarcoma
- 6. Global Market Analysis and Forecast by Region
- 6.1. North America
- 6.2. Latin America
- 6.3. Europe
- 6.4. Japan
- 6.5. APEJ
- 6.6. MEA
- 7. North America Market Analysis and Forecast, By Country, 2017 to 2032
- 8. Latin America Market Analysis and Forecast, By Country, 2017 to 2032
- 9. Europe Market Analysis and Forecast, By Country, 2017 to 2032
- 10. Japan Market Analysis and Forecast, By Country, 2017 to 2032
- 11. APEJ Market Analysis and Forecast, By Country, 2017 to 2032
- 12. MEA Market Analysis and Forecast, By Country, 2017 to 2032
- 13. Company Profile
- 13.1. Abbott Laboratories
- 13.2. Thermo Fisher Scientific Inc.
- 13.3. Rosetta Genomics
- 13.4. Sysmex Corporation
- 13.5. Roche Holding AG
- 13.6. NanoString Technologies Inc
- 13.7. NeoGenomics Laboratories, Inc.
- 13.8. Quest Diagnostics Incorporated
- 13.9. Illumina, Inc.
- 13.10. Myriad Genetics Inc
- 14. Disclaimer and Contact Information
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 01: Global Market Value (US$ Mn), 2017 to 2021
TABLE 02: Global Market Value (US$ Mn), 2022 to 2032
TABLE 03: Global Market Value (US$ Mn) and Y-o-Y, 2015 to 2032
TABLE 04: Global Immunohistochemistry Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 05: Global Immunohistochemistry Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 06: Global Immunohistochemistry Segment Market Share, By Region 2017 to 2021
TABLE 07: Global Immunohistochemistry Segment Market Share, By Region 2022 to 2032
TABLE 08: Global Immunohistochemistry Segment Y-o-Y, By Region 2015 to 2032
TABLE 09: Global Urine Analysis Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 10: Global Urine Analysis Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 11: Global Urine Analysis Segment Market Share, By Region 2017 to 2021
TABLE 12: Global Urine Analysis Segment Market Share, By Region 2022 to 2032
TABLE 13: Global Urine Analysis Segment Y-o-Y, By Region 2015 to 2032
TABLE 14: Global Complete Blood Count Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 15: Global Complete Blood Count Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 16: Global Complete Blood Count Segment Market Share, By Region 2017 to 2021
TABLE 17: Global Complete Blood Count Segment Market Share, By Region 2022 to 2032
TABLE 18: Global Complete Blood Count Segment Y-o-Y, By Region 2015 to 2032
TABLE 19: Global Blood Chemistry Test Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 20: Global Blood Chemistry Test Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 21: Global Blood Chemistry Test Segment Market Share, By Region 2017 to 2021
TABLE 22: Global Blood Chemistry Test Segment Market Share, By Region 2022 to 2032
TABLE 23: Global Blood Chemistry Test Segment Y-o-Y, By Region 2015 to 2032
TABLE 24: Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 25: Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 26: Global Hospital Associated Labs Segment Market Share, By Region 2017 to 2021
TABLE 27: Global Hospital Associated Labs Segment Market Share, By Region 2022 to 2032
TABLE 28: Global Hospital Associated Labs Segment Y-o-Y, By Region 2015 to 2032
TABLE 29: Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 30: Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 31: Global Independent Diagnostic Laboratories Segment Market Share, By Region 2017 to 2021
TABLE 32: Global Independent Diagnostic Laboratories Segment Market Share, By Region 2022 to 2032
TABLE 33: Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2015 to 2032
TABLE 34: Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 35: Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 36: Global Cancer Research Institutes Segment Market Share, By Region 2017 to 2021
TABLE 37: Global Cancer Research Institutes Segment Market Share, By Region 2022 to 2032
TABLE 38: Global Cancer Research Institutes Segment Y-o-Y, By Region 2015 to 2032
TABLE 39: Global Others Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 40: Global Others Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 41: Global Others Segment Market Share, By Region 2017 to 2021
TABLE 42: Global Others Segment Market Share, By Region 2022 to 2032
TABLE 43: Global Others Segment Y-o-Y, By Region 2015 to 2032
TABLE 44: Global Renal Cell Carcinoma Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 45: Global Renal Cell Carcinoma Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 46: Global Renal Cell Carcinoma Segment Market Share, By Region 2017 to 2021
TABLE 47: Global Renal Cell Carcinoma Segment Market Share, By Region 2022 to 2032
TABLE 48: Global Renal Cell Carcinoma Segment Y-o-Y, By Region 2015 to 2032
TABLE 49: Global Transitional Cell Carcinoma Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 50: Global Transitional Cell Carcinoma Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 51: Global Transitional Cell Carcinoma Segment Market Share, By Region 2017 to 2021
TABLE 52: Global Transitional Cell Carcinoma Segment Market Share, By Region 2022 to 2032
TABLE 53: Global Transitional Cell Carcinoma Segment Y-o-Y, By Region 2015 to 2032
TABLE 54: Global Wilms Tumor Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 55: Global Wilms Tumor Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 56: Global Wilms Tumor Segment Market Share, By Region 2017 to 2021
TABLE 57: Global Wilms Tumor Segment Market Share, By Region 2022 to 2032
TABLE 58: Global Wilms Tumor Segment Y-o-Y, By Region 2015 to 2032
TABLE 59: Global Kidney Lymphoma Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 60: Global Kidney Lymphoma Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 61: Global Kidney Lymphoma Segment Market Share, By Region 2017 to 2021
TABLE 62: Global Kidney Lymphoma Segment Market Share, By Region 2022 to 2032
TABLE 63: Global Kidney Lymphoma Segment Y-o-Y, By Region 2015 to 2032
TABLE 64: Global Kidney Sarcoma Segment Value (US$ Mn), By Region 2017 to 2021
TABLE 65: Global Kidney Sarcoma Segment Value (US$ Mn), By Region 2022 to 2032
TABLE 66: Global Kidney Sarcoma Segment Market Share, By Region 2017 to 2021
TABLE 67: Global Kidney Sarcoma Segment Market Share, By Region 2022 to 2032
TABLE 68: Global Kidney Sarcoma Segment Y-o-Y, By Region 2015 to 2032
TABLE 69: North America Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 70: North America Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 71: North America Market Value (US$ Mn), By End User 2017 to 2021
TABLE 72: North America Market Value (US$ Mn), By End User 2022 to 2032
TABLE 73: North America Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 74: North America Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 75: Latin America Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 76: Latin America Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 77: Latin America Market Value (US$ Mn), By End User 2017 to 2021
TABLE 78: Latin America Market Value (US$ Mn), By End User 2022 to 2032
TABLE 79: Latin America Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 80: Latin America Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 81: Europe Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 82: Europe Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 83: Europe Market Value (US$ Mn), By End User 2017 to 2021
TABLE 84: Europe Market Value (US$ Mn), By End User 2022 to 2032
TABLE 85: Europe Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 86: Europe Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 87: Japan Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 88: Japan Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 89: Japan Market Value (US$ Mn), By End User 2017 to 2021
TABLE 90: Japan Market Value (US$ Mn), By End User 2022 to 2032
TABLE 91: Japan Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 92: Japan Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 93: APEJ Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 94: APEJ Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 95: APEJ Market Value (US$ Mn), By End User 2017 to 2021
TABLE 96: APEJ Market Value (US$ Mn), By End User 2022 to 2032
TABLE 97: APEJ Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 98: APEJ Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 99: MEA Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 100: MEA Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 101: MEA Market Value (US$ Mn), By End User 2017 to 2021
TABLE 102: MEA Market Value (US$ Mn), By End User 2022 to 2032
TABLE 103: MEA Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 104: MEA Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 105: US Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 106: US Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 107: US Market Value (US$ Mn), By End User 2017 to 2021
TABLE 108: US Market Value (US$ Mn), By End User 2022 to 2032
TABLE 109: US Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 110: US Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 111: Canada Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 112: Canada Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 113: Canada Market Value (US$ Mn), By End User 2017 to 2021
TABLE 114: Canada Market Value (US$ Mn), By End User 2022 to 2032
TABLE 115: Canada Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 116: Canada Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 117: Brazil Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 118: Brazil Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 119: Brazil Market Value (US$ Mn), By End User 2017 to 2021
TABLE 120: Brazil Market Value (US$ Mn), By End User 2022 to 2032
TABLE 121: Brazil Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 122: Brazil Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 123: Mexico Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 124: Mexico Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 125: Mexico Market Value (US$ Mn), By End User 2017 to 2021
TABLE 126: Mexico Market Value (US$ Mn), By End User 2022 to 2032
TABLE 127: Mexico Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 128: Mexico Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 129: Argentina Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 130: Argentina Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 131: Argentina Market Value (US$ Mn), By End User 2017 to 2021
TABLE 132: Argentina Market Value (US$ Mn), By End User 2022 to 2032
TABLE 133: Argentina Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 134: Argentina Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 135: Germany Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 136: Germany Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 137: Germany Market Value (US$ Mn), By End User 2017 to 2021
TABLE 138: Germany Market Value (US$ Mn), By End User 2022 to 2032
TABLE 139: Germany Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 140: Germany Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 141: UK Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 142: UK Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 143: UK Market Value (US$ Mn), By End User 2017 to 2021
TABLE 144: UK Market Value (US$ Mn), By End User 2022 to 2032
TABLE 145: UK Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 146: UK Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 147: France Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 148: France Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 149: France Market Value (US$ Mn), By End User 2017 to 2021
TABLE 150: France Market Value (US$ Mn), By End User 2022 to 2032
TABLE 151: France Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 152: France Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 153: Spain Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 154: Spain Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 155: Spain Market Value (US$ Mn), By End User 2017 to 2021
TABLE 156: Spain Market Value (US$ Mn), By End User 2022 to 2032
TABLE 157: Spain Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 158: Spain Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 159: Italy Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 160: Italy Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 161: Italy Market Value (US$ Mn), By End User 2017 to 2021
TABLE 162: Italy Market Value (US$ Mn), By End User 2022 to 2032
TABLE 163: Italy Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 164: Italy Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 165: Nordic Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 166: Nordic Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 167: Nordic Market Value (US$ Mn), By End User 2017 to 2021
TABLE 168: Nordic Market Value (US$ Mn), By End User 2022 to 2032
TABLE 169: Nordic Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 170: Nordic Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 171: Japan Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 172: Japan Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 173: Japan Market Value (US$ Mn), By End User 2017 to 2021
TABLE 174: Japan Market Value (US$ Mn), By End User 2022 to 2032
TABLE 175: Japan Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 176: Japan Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 177: China Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 178: China Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 179: China Market Value (US$ Mn), By End User 2017 to 2021
TABLE 180: China Market Value (US$ Mn), By End User 2022 to 2032
TABLE 181: China Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 182: China Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 183: India Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 184: India Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 185: India Market Value (US$ Mn), By End User 2017 to 2021
TABLE 186: India Market Value (US$ Mn), By End User 2022 to 2032
TABLE 187: India Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 188: India Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 189: Malaysia Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 190: Malaysia Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 191: Malaysia Market Value (US$ Mn), By End User 2017 to 2021
TABLE 192: Malaysia Market Value (US$ Mn), By End User 2022 to 2032
TABLE 193: Malaysia Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 194: Malaysia Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 195: Thailand Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 196: Thailand Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 197: Thailand Market Value (US$ Mn), By End User 2017 to 2021
TABLE 198: Thailand Market Value (US$ Mn), By End User 2022 to 2032
TABLE 199: Thailand Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 200: Thailand Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 201: Singapore Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 202: Singapore Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 203: Singapore Market Value (US$ Mn), By End User 2017 to 2021
TABLE 204: Singapore Market Value (US$ Mn), By End User 2022 to 2032
TABLE 205: Singapore Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 206: Singapore Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 207: Australia Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 208: Australia Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 209: Australia Market Value (US$ Mn), By End User 2017 to 2021
TABLE 210: Australia Market Value (US$ Mn), By End User 2022 to 2032
TABLE 211: Australia Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 212: Australia Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 213: GCC Countries Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 214: GCC Countries Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 215: GCC Countries Market Value (US$ Mn), By End User 2017 to 2021
TABLE 216: GCC Countries Market Value (US$ Mn), By End User 2022 to 2032
TABLE 217: GCC Countries Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 218: GCC Countries Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 219: South Africa Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 220: South Africa Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 221: South Africa Market Value (US$ Mn), By End User 2017 to 2021
TABLE 222: South Africa Market Value (US$ Mn), By End User 2022 to 2032
TABLE 223: South Africa Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 224: South Africa Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 225: Nigeria Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 226: Nigeria Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 227: Nigeria Market Value (US$ Mn), By End User 2017 to 2021
TABLE 228: Nigeria Market Value (US$ Mn), By End User 2022 to 2032
TABLE 229: Nigeria Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 230: Nigeria Market Value (US$ Mn), By Indication 2022 to 2032
TABLE 231: Israel Market Value (US$ Mn), By Test Type 2017 to 2021
TABLE 232: Israel Market Value (US$ Mn), By Test Type 2022 to 2032
TABLE 233: Israel Market Value (US$ Mn), By End User 2017 to 2021
TABLE 234: Israel Market Value (US$ Mn), By End User 2022 to 2032
TABLE 235: Israel Market Value (US$ Mn), By Indication 2017 to 2021
TABLE 236: Israel Market Value (US$ Mn), By Indication 2022 to 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 01: Global Market Value (US$ Mn), 2017 to 2021
FIG. 02: Global Market Value (US$ Mn) Forecast, 2022 to 2032
FIG. 03: Global Market Value (US$ Mn) and Y-o-Y, 2015 to 2032
FIG. 04: Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 05: Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 06: Global Immunohistochemistry Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 07: Global Urine Analysis Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 08: Global Urine Analysis Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 09: Global Urine Analysis Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 10: Global Complete Blood Count Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 11: Global Complete Blood Count Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 12: Global Complete Blood Count Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 13: Global Blood Chemistry Test Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 14: Global Blood Chemistry Test Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 15: Global Blood Chemistry Test Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 16: Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 17: Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 18: Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 19: Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 20: Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 21: Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 22: Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 23: Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 24: Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 25: Global Others Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 26: Global Others Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 27: Global Others Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 28: Global Renal Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 29: Global Renal Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 30: Global Renal Cell Carcinoma Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 31: Global Transitional Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 32: Global Transitional Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 33: Global Transitional Cell Carcinoma Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 34: Global Wilms Tumor Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 35: Global Wilms Tumor Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 36: Global Wilms Tumor Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 37: Global Kidney Lymphoma Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 38: Global Kidney Lymphoma Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 39: Global Kidney Lymphoma Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 40: Global Kidney Sarcoma Segment Market Value (US$ Mn) By Region, 2017 to 2021
FIG. 41: Global Kidney Sarcoma Segment Market Value (US$ Mn) By Region, 2022 to 2032
FIG. 42: Global Kidney Sarcoma Segment Y-o-Y Growth Rate, By Region, 2015 to 2032
FIG. 43: North America Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 44: North America Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 45: North America Market Value (US$ Mn), By End User 2017 to 2021
FIG. 46: North America Market Value (US$ Mn), By End User 2022 to 2032
FIG. 47: North America Market Value (US$ Mn), By Indication 2017 to 2021
FIG. 48: North America Market Value (US$ Mn), By Indication 2022 to 2032
FIG. 49: Latin America Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 50: Latin America Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 51: Latin America Market Value (US$ Mn), By End User 2017 to 2021
FIG. 52: Latin America Market Value (US$ Mn), By End User 2022 to 2032
FIG. 53: Latin America Market Value (US$ Mn), By Indication 2017 to 2021
FIG. 54: Latin America Market Value (US$ Mn), By Indication 2022 to 2032
FIG. 55: Europe Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 56: Europe Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 57: Europe Market Value (US$ Mn), By End User 2017 to 2021
FIG. 58: Europe Market Value (US$ Mn), By End User 2022 to 2032
FIG. 59: Europe Market Value (US$ Mn), By Indication 2017 to 2021
FIG. 60: Europe Market Value (US$ Mn), By Indication 2022 to 2032
FIG. 61: Japan Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 62: Japan Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 63: Japan Market Value (US$ Mn), By End User 2017 to 2021
FIG. 64: Japan Market Value (US$ Mn), By End User 2022 to 2032
FIG. 65: Japan Market Value (US$ Mn), By Indication 2017 to 2021
FIG. 66: Japan Market Value (US$ Mn), By Indication 2022 to 2032
FIG. 67: APEJ Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 68: APEJ Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 69: APEJ Market Value (US$ Mn), By End User 2017 to 2021
FIG. 70: APEJ Market Value (US$ Mn), By End User 2022 to 2032
FIG. 71: APEJ Market Value (US$ Mn), By Indication 2017 to 2021
FIG. 72: APEJ Market Value (US$ Mn), By Indication 2022 to 2032
FIG. 73: MEA Market Value (US$ Mn), By Test Type 2017 to 2021
FIG. 74: MEA Market Value (US$ Mn), By Test Type 2022 to 2032
FIG. 75: MEA Market Value (US$ Mn), By End User 2017 to 2021
FIG. 76: MEA Market Value (US$ Mn), By End User 2022 to 2032
FIG. 77: MEA Market Value (US$ Mn), By Indication 2017 to 2021
FIG. 78: MEA Market Value (US$ Mn), By Indication 2022 to 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Which segment is expected to dominate the global kidney cancer diagnostics market during 2022?
In 2022, the immunohistochemistry by test type is expected to occupy a 65% market share.
What will be the growth rate of the global kidney cancer diagnostics market during the forecast period?
The global kidney cancer diagnostics market is expected to grow with a 7% CAGR during 2022 to 2032.
What is the present market value of the kidney cancer diagnostics industry?
The global kidney cancer diagnostics market is currently worth more than US$ 780 Million.
What will be the projected market size of the kidney cancer diagnostics market by 2032?
By 2032, the global kidney cancer diagnostics market is projected to reach a market size of US$ 1.4 Billion.
At what rate did the kidney cancer diagnostics market flourish from 2017 to 2021?
From 2017 to 2021, the kidney cancer diagnostics market grew at a CAGR of 5.8%.
What will be the outlook of the kidney cancer diagnostics end-user segment during the forecast period?
The hospital-associated labs segment is projected to hold a global market share of 40% in 2022.
How is the US kidney cancer diagnostics market projected to grow during 2022 to 2032?
The US is predicted to acquire 35% of the global market share in 2022.
What was the outlook of the Chinese kidney cancer diagnostics market during 2022?
The Chinese region is forecast to have a CAGR of 5.8% over the projection period of 2022 to 2032.
Kidney Cancer Diagnostics Market